Product news

Share this article:
Biovail Corporation received FDA approval for its NDA for Aplenzin (formerly known as BVF-033), a once-daily formulation of bupropion hydrobromide developed by Biovail for the treatment of depression in adults. Biovail remains partnership discussions for the commercialization rights for Aplenzin in the US.

The FDA approved Shire's Vyvanse (lisdexamfetamine dimesylate) for the treatment of ADHD in adults.  Vyvanse was first introduced in July 2007 for the treatment of ADHD in children aged 6 to 12 years.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.

India's Marck gets FDA Warning Letter

Inspectors of Marck Biosciences found an array of problems during a October-November 2013 inspection, including mold near a sterile area that was so bad "the room had 'partially caved in.'"

DOJ closes Brilinta investigation

AstraZeneca announced the end of the investigation Tuesday.